Yun Bian1, Jing Li1, Kai Cao1, Xu Fang1, Hui Jiang2, Chao Ma1, Gang Jin3, Jianping Lu1, Li Wang4. 1. Department of Radiology, Changhai Hospital, The Navy Military Medical University, 168 Changhai Road, Shanghai, 200433, China. 2. Department of Pathology, Changhai Hospital, The Navy Military Medical University, Shanghai, China. 3. Department of Pancreatic Surgery, Changhai Hospital, The Navy Military Medical University, Shanghai, China. 4. Department of Pathology, Changhai Hospital, The Navy Military Medical University, Shanghai, China. wangli_changhai@163.com.
Abstract
PURPOSE: We aimed to explore the relationship between the magnetic resonance imaging (MRI) radiomic score (rad-score) and the grades of non-functioning pancreatic neuroendocrine tumors (NF-pNETs) and evaluate the potential of the calculated MRI rad-score to differentiate grade 1 from grade 2/3 NF-pNETs. METHODS: This retrospective study assessed 157 patients with surgically resected, pathologically confirmed NF-pNETs who underwent magnetic resonance scans from November 2012 to December 2019. Radiomic features were extracted from arterial and portal venous MRI. The least absolute shrinkage and selection operator method were used to select the features. Multivariate logistic regression models were used to analyze the association between the MRI rad-score and NF-pNET grades. The MRI rad-score performance was assessed based on its discriminative ability and clinical usefulness. RESULTS: The MRI rad-score, which consisted of seven selected features, was significantly associated with the NF-pNET grades. Every 1-point increase in the rad-score was associated with a 35% increased risk of grade 2/3 disease. The score also showed high accuracy (area under the curve = 0.775). The best cut-off point for maximal sensitivity and specificity was at 0.41. In the decision curves, when the threshold probability was higher than 0.3, the rad-score used in this study to distinguish grades 1 and 2/3 NF-pNETs offered more benefits than the use of a treat-all-patients or a treat-none scheme. CONCLUSIONS: The MRI rad-score showed a significant association with the grades of NF-pNETs. Thus, it may be used as a valuable non-invasive tool for differential NF-pNET grading.
PURPOSE: We aimed to explore the relationship between the magnetic resonance imaging (MRI) radiomic score (rad-score) and the grades of non-functioning pancreatic neuroendocrine tumors (NF-pNETs) and evaluate the potential of the calculated MRI rad-score to differentiate grade 1 from grade 2/3 NF-pNETs. METHODS: This retrospective study assessed 157 patients with surgically resected, pathologically confirmed NF-pNETs who underwent magnetic resonance scans from November 2012 to December 2019. Radiomic features were extracted from arterial and portal venous MRI. The least absolute shrinkage and selection operator method were used to select the features. Multivariate logistic regression models were used to analyze the association between the MRI rad-score and NF-pNET grades. The MRI rad-score performance was assessed based on its discriminative ability and clinical usefulness. RESULTS: The MRI rad-score, which consisted of seven selected features, was significantly associated with the NF-pNET grades. Every 1-point increase in the rad-score was associated with a 35% increased risk of grade 2/3 disease. The score also showed high accuracy (area under the curve = 0.775). The best cut-off point for maximal sensitivity and specificity was at 0.41. In the decision curves, when the threshold probability was higher than 0.3, the rad-score used in this study to distinguish grades 1 and 2/3 NF-pNETs offered more benefits than the use of a treat-all-patients or a treat-none scheme. CONCLUSIONS: The MRI rad-score showed a significant association with the grades of NF-pNETs. Thus, it may be used as a valuable non-invasive tool for differential NF-pNET grading.
Authors: Olca Basturk; Zhaohai Yang; Laura H Tang; Ralph H Hruban; Volkan Adsay; Chad M McCall; Alyssa M Krasinskas; Kee-Taek Jang; Wendy L Frankel; Serdar Balci; Carlie Sigel; David S Klimstra Journal: Am J Surg Pathol Date: 2015-05 Impact factor: 6.394
Authors: H Sorbye; S Welin; S W Langer; L W Vestermark; N Holt; P Osterlund; S Dueland; E Hofsli; M G Guren; K Ohrling; E Birkemeyer; E Thiis-Evensen; M Biagini; H Gronbaek; L M Soveri; I H Olsen; B Federspiel; J Assmus; E T Janson; U Knigge Journal: Ann Oncol Date: 2012-09-11 Impact factor: 32.976
Authors: Robert T Jensen; Guillaume Cadiot; Maria L Brandi; Wouter W de Herder; Gregory Kaltsas; Paul Komminoth; Jean-Yves Scoazec; Ramon Salazar; Alain Sauvanet; Reza Kianmanesh Journal: Neuroendocrinology Date: 2012-02-15 Impact factor: 4.914
Authors: Calogero Casà; Antonio Piras; Andrea D'Aviero; Francesco Preziosi; Silvia Mariani; Davide Cusumano; Angela Romano; Ivo Boskoski; Jacopo Lenkowicz; Nicola Dinapoli; Francesco Cellini; Maria Antonietta Gambacorta; Vincenzo Valentini; Gian Carlo Mattiucci; Luca Boldrini Journal: Ther Adv Gastrointest Endosc Date: 2022-03-16
Authors: Matteo Ferro; Ottavio de Cobelli; Gennaro Musi; Francesco Del Giudice; Giuseppe Carrieri; Gian Maria Busetto; Ugo Giovanni Falagario; Alessandro Sciarra; Martina Maggi; Felice Crocetto; Biagio Barone; Vincenzo Francesco Caputo; Michele Marchioni; Giuseppe Lucarelli; Ciro Imbimbo; Francesco Alessandro Mistretta; Stefano Luzzago; Mihai Dorin Vartolomei; Luigi Cormio; Riccardo Autorino; Octavian Sabin Tătaru Journal: Ther Adv Urol Date: 2022-07-04